Survodutide
Survodutide is a peptide, indexed here under Incretin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Incretin receptor agonists |
| CAS registry number | 2805997-46-8[1] |
| PubChem CID | 171378821[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C192H289N47O61[1] |
| Molecular weight | 4232 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Survodutide, development code BI 456906, is described in the retrieved literature as a glucagon and GLP-1 receptor dual agonist. A 2022 Molecular Metabolism paper reports its discovery and preclinical pharmacology, and 2023 Diabetes, Obesity and Metabolism papers report phase I safety, tolerability, pharmacokinetic and pharmacodynamic studies.
Clinical records include a 2024 Lancet Diabetes and Endocrinology randomised placebo-controlled dose-finding trial in obesity, a 2024 New England Journal of Medicine phase 2 randomised trial in MASH and fibrosis, a 2024 Diabetologia paper on dose-response effects on HbA1c and bodyweight, a 2024 Journal of Hepatology paper on efficacy, tolerability and pharmacokinetics, a 2026 New England Journal of Medicine paper on once-weekly administration in adults with obesity, and 2024 and 2025 papers describing the design of the SYNCHRONIZE phase 3 and cardiovascular outcomes trials.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12]Reported mechanism
A glucagon receptor and GLP-1 receptor dual agonist, per the retrieved records.
[3, 6]Stated in the titles of the cited 2022 Molecular Metabolism and 2024 Lancet Diabetes and Endocrinology papers.
Targets named in the cited records: GLP-1 receptor, glucagon receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Survodutide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- BI 456906
Where this page sits
Research records
Cited research records for Survodutide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Mazdutide — Incretin receptor agonists
- Retatrutide — Incretin receptor agonists
Named targets in the cited records
Class page: Incretin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Survodutide?
Survodutide, development code BI 456906, is described in the retrieved literature as a glucagon and GLP-1 receptor dual agonist. A 2022 Molecular Metabolism paper reports its discovery and preclinical pharmacology, and 2023 Diabetes, Obesity and Metabolism papers report phase I safety, tolerability, pharmacokinetic and pharmacodynamic studies.
Which class is Survodutide indexed under?
Survodutide is indexed under Incretin receptor agonists. Incretin receptor agonists are synthetic peptides that bind one or more of the incretin and glucagon family receptors, principally the glucagon-like peptide-1 receptor.
What does the FDA application register show for Survodutide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 171378821, survodutide. PubChem, National Library of Medicine (2026). pubchem:171378821
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:survodutide
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular metabolism (2022). pmid:36356832
- Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism (2023). pmid:36527386
- A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity. Diabetes, obesity & metabolism (2023). pmid:36974349
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The lancet. Diabetes & endocrinology (2024). pmid:38330987
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England journal of medicine (2024). pmid:38847460
- Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2024). pmid:38095657
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. Journal of hepatology (2024). pmid:38857788
- Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine (2026). pmid:42253238
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Obesity (Silver Spring, Md.) (2025). pmid:39495965
- Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC. Heart failure (2024). pmid:39453356
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.